Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.

Journal of investigative medicine high impact case reports - 1 Jan 2000

Chan Kok Hoe, Li Ningjing, Lador Ran, Amsbaugh Mark, Gonzalez Anneliese, Cen Putao

Abstract excerpt

The Von-Hippel-Lindau (VHL) gene, acting as a tumor suppressor, plays a crucial role in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). Approximately 90% of individuals with advanced ccRCC exhibit somatic mutations in the VHL gene. Belzutifan, orally administered small-molecule inhibitor of hypoxia-induced factor-2α, has demonstrated promising efficacy in solid tumors associated with germline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Basic Helix-Loop-Helix Transcription Factors
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Indenes

Share to Kidney Neoplasms

Share to Mutation

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 38344974
DOI: 10.1177/23247096241231641
PMCID: PMC10863383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.PMID 38344974Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinomaSemantic proximity Read ↗

Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal CancerSemantic proximity Read ↗

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.Semantic proximity Read ↗

Real-world efficacy and safety of belzutifan in patients with metastatic renal cell carcinoma: a multicenter retrospective study in JapanSemantic proximity Read ↗

Renal Cell Carcinoma in von Hippel–Lindau Disease—From Tumor Genetics to Novel Therapeutic StrategiesSemantic proximity Read ↗

State of the science: an update on renal cell carcinoma.Semantic proximity Read ↗

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic responseSemantic proximity Read ↗

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor HypoxiaSemantic proximity Read ↗

Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discoverySemantic proximity Read ↗

Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.Semantic proximity Read ↗

A novel mechanism of HIF2-dependent PLK1-mediated metastasis and drug resistance of clear cell Renal Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.